Immunotherapy Focus Sanavia Oncology is a NYC biotech focused on developing immunotherapies for cancer patients who lack effective existing options, presenting a clear opportunity to partner on novel treatments that address high-need markets.

Academic pedigree The team comprises researchers from top institutions (MSKCC, Rockefeller, Weill Cornell, Columbia), which can facilitate credibility in collaborations, joint development, and access to academic partnerships.

Proprietary Platform Their platform combines AI and modern immunology to identify cancer-specific epitopes and select antibodies from high-throughput data, offering a potential differentiator for collaborations in targeted therapies and precision immuno-oncology.

Early-stage traction Revenue is in the low single to mid single digits with a small headcount, indicating a lean, early-stage company that may be seeking strategic partnerships, licensing deals, or co-development arrangements to scale.

Tech & readiness Technology stack and digital presence show readiness for tech-enabled collaboration, potential for joint V-Corp or CRO partnerships, and scalable data-driven programs with pharma partners seeking accelerated discovery.